Aggregated price index with volume information
Summary:
- Biotechnology stocks up 1.5% on average while median return up 1.0% in a day
- Biotechnology stocks up 0.6% on average while median return up -0.0% in a week
- Biotechnology stocks down 8.7% on average while median return down 11.1% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $ABIO 109.4%, $MESO 78.8%, $ALPN 67.0%, $GALT 43.2%, $ALDX 27.6%
- 1M losers are : Losers for past month are $RCEL -48.4%, $GLYC -48.4%, $KOD -56.0%, $PACB -60.5%, $ENLV -62.7%
- 1W winners are : Winners for past week are $INMB 34.9%, $IGMS 30.6%, $PDSB 23.4%, $ATHE 20.9%, $MESO 19.8%
- 1W losers are : Losers for past week are $NXTC -15.6%, $ALLO -16.7%, $CABA -17.5%, $ADVM -19.0%, $FATE -20.7%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 12.9%, for the past 3 months is 11.7%
In the past month for a 5 days rolling window, the highest corrrelation is 32.4%, the lowest correlation is 5.8%, the latest correlation is 22.2%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 71.9% between ABCM and ALPN
The lowest correlation is -48.3% between ALKS and ALPN
Sector Update: Health Care Stocks Edge Higher Late Afternoon
The IRA adds another hurdle to an already challenging research landscape, according to a study from the Pioneer Institute.
LONDON, April 26, 2024--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.
On Puma Biotechnology's (PBYI) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.
Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., April 26, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, released its 2023 Responsible Business & Sustainability Report highlighting the Company’s strategy, the progress it has made towards existing goals, and how it intends to achieve its bold new targets.
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.
Ovid Therapeutics (OVID) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.